Osia 2 Pediatric Expansion Study

Conductive Hearing Loss Clinical Trial

Official title:

A Pivotal, Prospective, Multi-center, Open-label Study Evaluating the Safety and Effectiveness of the CochlearTM Osia® 2 System in a Pediatric Population.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05000931
• Other study ID #: CAM 5766
• Status: Completed
• Phase: N/A
• Start date: January 26, 2022
• Est. completion date: March 14, 2024

Study information

• Verified date: March 2024
• Source: Cochlear
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

Description:

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD). Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Due to the success of the Osia 2 system in the United States within the currently indicated patient population, clinical providers have since requested the ability to use the Osia 2 system in children aged 11 years and younger who meet the audiometric requirements. As the Osia 2 system is based on existing bone conduction and cochlear implant technologies which each possess a younger age of implantation requirement (5 years for bone conduction and 9 months for cochlear implantation), the current proposal is to align the age at implantation requirement with existing surgical bone conduction technology such as the Baha Connect and Baha Attract Systems to 5 years of age. Therefore, the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 14, 2024
• Est. primary completion date: September 22, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 11 Years

Eligibility

Inclusion Criteria:

1. Subjects aged 5 to 11 years of age with the following audiometric criterion:

• A conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL. OR
• A profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).

2. Prior experience with amplified sound through properly fitted amplification device such as a hearing aid, a CROS device, or a bone conduction device on a softband or sound arc.

3. Parent or legal guardian who is willing and able to provide written informed consent for the study participant. Note: Subjects may include individuals seeking new implantation unilaterally (in one ear) or individuals already implanted with a bone-anchored device seeking a second-side implant (sequential bilateral)

Exclusion Criteria:

1. Insufficient bone quality or quantity to support implantation of both the BI300 Implant and the OSI200 Implant.

2. Chronic or non-revisable vestibular or balance disorders that could prevent benefit from the device, as determined by the investigator.

3. Abnormally progressive hearing loss.

4. Evidence that hearing loss is bilateral retro cochlear or bilateral central origin.

5. Evidence of conditions that would prevent speech recognition improvement as determined by the investigator.

6. Skin or scalp conditions that may preclude attachment of the Sound Processor or that may interfere with the use of the Sound Processor.

7. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.

8. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.

9. Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.

10. Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Osia 2 system as determined by the investigator.

11. Individuals undergoing simultaneous single-stage aural atresia or microtia repair due to the increased risk of skin complications associated with ear reconstruction.

Related Conditions & MeSH terms

• Conductive Hearing Loss
• Deafness
• Hearing Loss
• Hearing Loss, Conductive
• Hearing Loss, Mixed Conductive-Sensorineural
• Mixed Hearing Loss
• Single-Sided Deafness

Intervention

Device:
• Osia 2 System
Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Texas Children's Hospital	Houston	Texas
United States	Children's Minnesota	Minneapolis	Minnesota
United States	Stanford University	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Barrow Neurological Institute	Phoenix	Arizona
United States	Rady Children's Hospital	San Diego	California

Sponsors (3)

Lead Sponsor	Collaborator
Cochlear	Analytical Solutions Group, Inc., R. P. Chiacchierini Consulting, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse events quantified by type, frequency, and severity between surgery and 6-months post-surgery.		6 months post-surgery
Secondary	Change from baseline to 6-month post-surgery in parental questionnaires.		Baseline before surgery, 6 months post-surgery
Secondary	Change from baseline to 4-weeks post-surgery in unaided bone conduction thresholds.		Baseline before surgery, 4 weeks post-surgery
Secondary	Change in word recognition using CNC words presented in quiet from baseline to 6-months post-surgery.		Baseline before surgery, 6 months post-surgery
Secondary	Change in sentence recognition in noise using the BKB-SIN from baseline to 6-months post-surgery.		Baseline before surgery, 6 months post-surgery